Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Cancers|January 11, 2024
Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary ChemoradiationMaximilian Linxweiler, Matthias Schneider, Sandrina Körner, et al.
Radiation Oncology (London, England)|April 1, 2021
Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?Thomas Weissmann, Daniel Höfler, Markus Hecht, et al.
Neoplasia (New York, N.Y.)|October 19, 2023
Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cellsFridolin Grottker, Simon Gehre, Clara M Reichardt, et al.
Cells|April 30, 2021
Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 MonotherapyJian-Guo Zhou, Bo Liang, Jian-Guo Liu, et al.
Iscience|December 6, 2024
Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLCJunzhu Xu, Haitao Wang, Chi Zhang, et al.
Therapeutic Advances in Medical Oncology|August 24, 2023
Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trialsJian-Guo Zhou, Yu Zeng, Haitao Wang, et al.
Cancers|September 28, 2024
Tumor-Associated Neutrophils Are a Negative Prognostic Factor in Early Luminal Breast Cancers Lacking Immunosuppressive Macrophage RecruitmentEva Schmidt, Luitpold Distel, Ramona Erber, et al.
Cancers|January 11, 2022
Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal CancerBarbara Schuster, Markus Hecht, Manfred Schmidt, et al.
Frontiers in Oncology|November 30, 2020
Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint InhibitorsPhilipp Schubert, Sandra Rutzner, Markus Eckstein, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2020
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapyClaudia Schweizer, Philipp Schubert, Sandra Rutzner, et al.
Pageof 13